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Objectives This study investigated the differences in specific causes of post–coronary artery bypass graft surgery (CABG)
deaths in the PLATO (Platelet Inhibition and Patient Outcomes) trial.
Background In the PLATO trial, patients assigned to ticagrelor compared with clopidogrel and who underwent CABG had sig-
nificantly lower total and cardiovascular mortality.
Methods In the 1,261 patients with CABG performed within 7 days after stopping study drug, reviewers blinded to treat-
ment assignment classified causes of death into subcategories of vascular and nonvascular, and specifically
identified bleeding or infection events that either caused or subsequently contributed to death.
Results Numerically more vascular deaths occurred in the clopidogrel versus the ticagrelor group related to myocardial
infarction (14 vs. 10), heart failure (9 vs. 6), arrhythmia or sudden death (9 vs. 3), and bleeding, including hem-
orrhagic stroke (7 vs. 2). Clopidogrel was also associated with an excess of nonvascular deaths related to infec-
tion (8 vs. 2). Among factors directly causing or contributing to death, bleeding and infections were more com-
mon in the clopidogrel group compared with the ticagrelor group (infections: 16 vs. 6, p  0.05, and bleeding:
27 vs. 9, p  0.01, for clopidogrel and ticagrelor, respectively).
Conclusions The mortality reduction with ticagrelor versus clopidogrel following CABG in the PLATO trial was associated with
fewer deaths from cardiovascular, bleeding, and infection complications. (Platelet Inhibition and Patient Out-
comes [PLATO]; NCT00391872) (J Am Coll Cardiol 2012;60:1623–30) © 2012 by the American College of
Cardiology Foundation
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tion and Patient Outcomes) trial
(NCT00391872) demonstrated
that ticagrelor was superior to
clopidogrel for the prevention of
cardiovascular (CV) events, in-
cluding myocardial infarction,
CV death, and stent thrombosis,
and numerically for total death in
patients with acute coronary syn-
dromes (ACS) (1). In the subset
of patients who underwent coro-
nary artery bypass graft surgery
(CABG) after randomization and received study drug
within 7 days of surgery (n  1,261), ticagrelor was
associated with a reduction in total and CV mortality (2). In
this subpopulation, a 50% relative reduction in total and CV
mortality was observed in patients randomized to ticagrelor
versus clopidogrel.
The underlying direct causes of and contributing factors
to mortality in the CABG-treated patients and the ability to
explain differences in outcomes between the treatment arms
have not been fully understood in the trial. There was no
difference in baseline characteristics and timing of CABG
between patients allocated to ticagrelor or clopidogrel (2).
Several mechanisms linked to the mode of action of ticagre-
lor, including its reversibility, more rapid offset of platelet
inhibitory effect, and attenuation of red blood cell adenosine
re-uptake have been hypothesized (3). In support of a
drug-related effect, the greatest mortality difference was
observed when the last dose of study drug was taken 2 to 4
days before surgery (2). The ticagrelor U.S. label and the
European Society of Cardiology non–ST-segment elevation
ACS guidelines recommend stopping ticagrelor 5 days
before CABG when possible.
The aim of this study was to investigate the causes of
CABG-related death in the PLATO trial by further clas-
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and Acronyms
ACS  acute coronary
syndromes
CABG  coronary artery
bypass graft surgery
CI  confidence interval
CV  cardiovascular
HR  hazard ratio
TIMI  Thrombolysis In
Myocardial InfarctionManuscript received March 30, 2012; revised manuscript received July 2, 2012,
accepted July 2, 2012.sifying, in a blinded fashion, all CABG-related deaths
according to direct and indirectly related causes.
Methods
Patients and study design. In the PLATO trial, ticagrelor
was compared with clopidogrel for the prevention of CV
events in ACS. Patients were randomly assigned to receive
ticagrelor or clopidogrel, administered in a double-blind,
double-dummy fashion. The trial recruited 18,624 patients
within 24 h of onset of ACS, with or without ST-segment
elevation, whether intended for interventional or medical
treatment. Randomized treatment continued for 6 to 12
months. The primary composite endpoint was myocardial
infarction, stroke, and vascular death up to and including 12
months after enrollment. The overall study design, popula-
tion, and outcomes have been published previously (1,4).
Ten percent (n  1,899) of the patients underwent CABG
post-randomization. Of these, 1,261 patients underwent
CABG within 7 days after the last intake of the study drug
(Fig. 1). The protocol recommended ticagrelor or its match-
ing placebo to be withheld for 24 to 72 h, and clopidogrel or
its matching placebo for 5 days prior to surgery.
Classification. In the present ancillary study, all post-
CABG deaths in patients undergoing surgery within 7 days
of the last intake of the study drug (n  87) were identified
and further independently categorized by 2 reviewers
blinded to treatment assignment. Disagreements were
grouped into major and minor disagreements. All major
disagreements were resolved in meetings as a consensus
decision with at least 3 reviewers present of whom 2 were
not the original reviewers. Minor disagreements were re-
solved by 2 reviewers.
The PLATO event adjudication committee originally
classified each death as either vascular or nonvascular, and
designated a time of death: these designations remained
unchanged. Reviewers for this study further subclassified
vascular deaths as sudden death; acute myocardial infarc-
tion; arrhythmia; heart failure/cardiogenic shock; cerebro-
vascular event (ischemic stroke, hemorrhagic stroke, isch-
Figure 1 Study Population
Study population undergoing coronary artery bypass graft surgery (CABG) by
randomized treatment assignment.
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hemorrhage); pulmonary embolism; peripheral arterial dis-
ease; hemorrhage (e.g., death in which a bleeding event
directly led to death within 7 days, subcategorized into
perioperative CABG-related bleeding, gastrointestinal
bleeding, and other bleeding); or other vascular death.
Nonvascular deaths were classified as primary infection/
sepsis (surgical site infection, urinary tract infection, blood
stream infection, respiratory tract infection, gastrointestinal
tract infection, CV system infection, other); pulmonary
causes; renal causes; gastrointestinal causes; multiple organ
dysfunction syndrome; malignancy; accident/trauma; sui-
cide; or other nonvascular death.
In addition to reviewing the primary cause of death,
bleeding or infections that could have contributed to death,
were identified. Bleeding contributing to death was defined
as an event not considered as the primary cause of death, but
a clinically overt bleeding event that was part of a causal
chain of events leading to death within 30 days of the bleed.
The bleeding events related to death were subclassified into
intra/post-operative CABG-related bleeding; intracranial
hemorrhage; gastrointestinal bleeding; or other bleeding. If
infection contributed to, but was not considered as the
primary cause of death, it was subclassified into surgical site
infection; urinary tract infection; bloodstream infection;
respiratory tract infection; gastrointestinal system infection;
CV system infection; and other infection.
Reviewers determined and agreed to the list of all
classification and subclassification categories before com-
mencing their blinded review of the clinical information in
the PLATO database.
Statistical analysis. The analyses comprised all patients
ndergoing CABG with last intake of the study drug within
days before surgery, with further analyses of the subgroup
f patients with post-CABG death. Baseline characteristics
nd procedures in hospital or at discharge were summarized
or all post-CABG deaths and the total CABG group using
requencies for categorical variables and medians with in-
erquartile intervals for continuous variables. Subcategorized
ascular and nonvascular deaths were described by treatment
roup using frequency tables. The Fisher exact test was used
o compare group frequencies. The time to death due to
nfection (primary cause of death or contributing to death)
nd death due to bleeding (primary cause or contributing)
ere analyzed with Cox proportional hazards model with
he treatment group as an independent variable. Cumulative
ncidence curves were obtained using the Kaplan-Meier
echnique. The proportional hazard assumptions were
hecked by log-cumulative hazard plots (data not shown).
azard ratios (HRs) and 95% confidence intervals (CIs)
ere calculated using Cox models. A p value 0.05 was
egarded as statistically significant. All analyses were done
ith SAS software (version 9.2, SAS Institute, Cary, North
arolina).Results
Patient characteristics. Baseline characteristics and treat-
ments and evaluations of the patients undergoing CABG
within 7 days of study drug cessation (n 1,261) and of the
subset of patients who died post-CABG (n 87) are shown
in Tables 1 and 2, and Online Table 1.
Vascular and nonvascular deaths subcategorized. There
were significantly more vascular deaths in the clopidogrel
group compared with the ticagrelor group. For clopidogrel,
there were numerically more vascular deaths attributed to
myocardial infarction, heart failure, sudden death/
arrhythmia, and hemorrhagic stroke/bleeding compared
with ticagrelor, but none of these differences were statisti-
cally significant (Table 3). For nonvascular deaths, there
were numerically, but not statistically significant, more infec-
tions as the primary cause of death in clopidogrel-treated
patients compared with ticagrelor-treated patients (Table 3).
The treatment effect on total and CV mortality was consis-
tent in most subgroups in the 1,261-patient population with
only a significant interaction for sex (Online Tables 2 and 3).
For 27 patients randomized to clopidogrel and 9 random-
ized to ticagrelor (p  0.01), bleeding contributed to death
or was directly related to death (Fig. 2A, Table 4). Similarly,
infections being the direct or contributing cause of death
were more common in patients randomized to clopidogrel
than to ticagrelor (16 vs. 6, p  0.05) (Fig. 2B, Table 4).
Time to death after CABG. Overall, bleeding as the
primary or contributing cause of death occurred more
frequently within the first month after CABG (Fig. 3A).
The estimated 12-month rates of bleeding directly causing
or contributing to death were 4.6% for clopidogrel versus
1.4% for ticagrelor, corresponding to a HR of 0.33 (95% CI:
0.15 to 0.70).
At 12 months post-CABG, the cumulative incidence of
combination of deaths contributing to or being primarily
caused by infection was 2.9% for patients randomized to
clopidogrel and 1% for ticagrelor (HR: 0.36; 95 % CI: 0.14
to 0.93) (Fig. 2B). The deaths related to infections were
evenly distributed over time during the first-month, 1- to
3-month, and more than 3-month time intervals among the
ticagrelor-treated patients (Fig. 3B).
Discussion
The main finding of this study is that the observed lower
mortality in post-CABG patients assigned to ticagrelor
compared with clopidogrel was explained, not only by lower
rates of CV deaths, but also by a reduction in bleeding and
infection events leading to death. In this study, bleeding as
the direct cause or as a contributing factor to death was
one-third as frequent in patients treated with ticagrelor
compared with clopidogrel (HR: 0.33; 95% CI: 0.15 to
0.70). These findings are seemingly in contrast to those of
the initial analyses of the PLATO CABG-population,
where no significant differences in bleeding overall between
the 2 treatment arms were observed, despite using several
CABG w
ery; PC
1626 Varenhorst et al. JACC Vol. 60, No. 17, 2012
Ticagrelor in Coronary Artery Bypass Surgery October 23, 2012:1623–30different bleeding definitions (2). However, this study fo-
cuses, in addition to the previous analyses, on bleeding
events that were contributing to death and those in which
bleeding was the primary cause of death. Ticagrelor was
associated with a lower bleeding rate compared with clopi-
dogrel. The more rapid offset of the platelet inhibitory effect
after ticagrelor discontinuation may be one reasonable
explanation for this association and a contributing factor
explaining the difference. This interpretation fits with the
observation that the greatest difference in mortality was
found when surgery was performed 2 to 4 days after the last
intake of the study drug. A longer time gap between drug
discontinuation and surgery might require bridging with
short-acting antithrombotic agents such as low-molecular-
weight heparins or glycoprotein IIb/IIIa inhibitors.
Clopidogrel is an irreversible platelet inhibitor, and nor-
mal platelet activity is not regained until 5 to 10 days after
discontinuation. Cessation of clopidogrel treatment is
therefore recommended at least 5 days before CABG
surgery in order to limit the risk of bleeding (5,6). Ticagre-
Baseline CharacteristicsTable 1 Baseline Characteristics
Death After CAB
Ticagrelor
(n  29)
Age, yrs 70 (58–76)
Age 75 yrs 11 (37.9%)
Women 16 (55.2%)
Weight, kg 66 (61–73)
Weight 60 kg 3 (18.8%)
BMI, kg/m2 25.5 (23.0–28.2)
Men 13 (44.8%)
Weight, kg 82 (76–90)
Weight 60 kg 1 (7.7%)
BMI, kg/m2 27.3 (25.6–30.3)
Race
White 24 (82.8%)
Black 2 (6.9%)
Asian 2 (6.9%)
Other 1 (3.4%)
Cardiovascular risk factors
Smoker 5 (17.2%)
Hypertension 21 (72.4%)
Dyslipidemia 14 (48.3%)
Diabetes 10 (34.5%)
Medical history
Angina pectoris 17 (58.6%)
Myocardial infarction 6 (20.7%)
Congestive heart failure 3 (10.3%)
Previous PCI 5 (17.2%)
Coronary artery bypass graft 1 (3.4%)
Transient ischemic attack 1 (3.4%)
Non-hemorrhagic stroke 1 (3.4%)
Peripheral arterial disease 2 (6.9%)
Chronic renal disease 2 (6.9%)
Values are median (interquartile range) or n (%). Patients underwent
BMI  body mass index; CABG  coronary artery bypass graft surglor, on the other hand, is a direct-acting, reversibly bindingP2Y12 inhibitor with a faster offset of platelet inhibition
after drug discontinuation compared with clopidogrel (7,8).
Moderate-to-poor responders to clopidogrel have a similar
time to recovery of platelet function compared with
ticagrelor-treated patients after cessation of treatment (9).
Thus, approximately a third of the patients with high levels
of platelet inhibition on clopidogrel need 7 or more days to
recover near-normal platelet reactivity, explaining why some
clopidogrel-treated patients may be particularly vulnerable
to serious hemorrhagic complications to CABG surgery,
especially if performed early.
The ticagrelor U.S. label and the European Society of
Cardiology guidelines on non–ST-segment elevation ACS
recommend stopping ticagrelor 5 days before CABG when
possible. The results of the PLATO CABG substudy (2)
and the present analyses suggest that the interval might be
shortened to 2 to 3 days. However, further studies are
required to define the optimal time point of stopping
ticagrelor before CABG surgery.
The PLATO trial enrolled a broad selection of patients
87) Total (N  1,261)
pidogrel
 58)
Ticagrelor
(n  632)
Clopidogrel
(n  629)
(60–78) 64 (56–71) 64 (56–71)
(34.5%) 86 (13.6%) 99 (15.7%)
(29.3%) 121 (19.1%) 145 (23.1%)
(60–80) 70 (64–80) 71 (63–80)
(11.8%) 16 (13.2%) 23 (15.9%)
(25.0–30.1) 26.8 (24.8–31.3) 27.1 (24.6–30.9)
(70.7%) 511 (80.9%) 484 (76.9%)
(64–85) 82 (73–92) 81 (72–90)
(14.6%) 15 (2.9%) 16 (3.3%)
(23.5–27.8) 27.6 (25.0–30.5) 26.9 (24.6–29.4)
(84.5%) 588 (93.0%) 588 (93.5%)
(3.4%) 8 (1.3%) 9 (1.4%)
(5.2%) 26 (4.1%) 23 (3.7%)
(6.9%) 10 (1.6%) 9 (1.4%)
(32.8%) 208 (32.9%) 185 (29.4%)
(70.7%) 433 (68.5%) 422 (67.1%)
(55.2%) 356 (56.3%) 328 (52.1%)
(41.4%) 193 (30.5%) 207 (32.9%)
(63.8%) 344 (54.4%) 327 (52.0%)
(27.6%) 124 (19.6%) 131 (20.8%)
(8.6%) 30 (4.7%) 22 (3.5%)
(15.5%) 58 (9.2%) 73 (11.6%)
(5.2%) 5 (0.8%) 14 (2.2%)
(5.2%) 21 (3.3%) 18 (2.9%)
(1.7%) 24 (3.8%) 25 (4.0%)
(8.6%) 43 (6.8%) 53 (8.4%)
(12.1%) 33 (5.2%) 27 (4.3%)
ithin 7 days after the last intake of the study drug.
I  percutaneous coronary intervention.G (n 
Clo
(n
69
20
17
68
2
26.8
41
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6
26.0
49
2
3
4
19
41
32
24
37
16
5
9
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3
1
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7with ACS within 24 h after symptom onset and before any
branc
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included a relatively large cohort of patients who needed
urgent CABG and thereby being exposed to clopidogrel or
ticagrelor within 7 days of CABG. Numerous observational
studies have documented an increased bleeding rate when
clopidogrel is used within 5 days before surgery (10–13),
and therefore, withholding clopidogrel at least 5 days before
surgery is endorsed by current guidelines (5,6,14). The
risk–benefit of continued dual antiplatelet treatment until
the time of CABG likely varies based on the clinical setting
and the urgency of the surgery. A meta-analysis by Nijjer et
al. (15) suggests that ACS patients requiring urgent CABG
should undergo this surgery without a delay for a
clopidogrel-free period. On the other hand, this proposal
does not take into consideration the variable levels of
platelet inhibition in patients taking clopidogrel and the
potentially greater bleeding risk in patients with adequate
levels of inhibition. In the PLATO trial, the protocol
recommended ticagrelor/placebo to be withheld for 24 to
72 h before operation, compared with 5 days for clopi-
Evaluations, Treatments, and Procedures in Hospital or at DischargTable 2 Evaluations, Treatments, and Procedures in Hospital o
Characteristic
Death After C
Ticagrelor (n  29)
Abnormal, physical findings 11 (37.9%)
Heart rate, beats/min 80 (70–91)
Systolic blood pressure, mm Hg 140 (118–145)
Diastolic blood pressure, mm Hg 80 (74–90)
Killip class 2 1 (3.4%)
Persistent ST-segment elevation 1 mm/LBBB/
final diagnosis STEMI
11 (37.9%)
TIMI STEMI risk score 2* 8 (72.7%)
Antithrombotic treatment in hospital
Aspirin before randomization 27 (93.1%)
Aspirin after randomization 28 (96.6%)
Unfractionated heparin 17 (58.6%)
Low-molecular-weight heparin 18 (62.1%)
Fondaparinux 2 (6.9%)
Bivalirudin 0 (0%)
Glycoprotein IIb/IIIa inhibitor 6 (20.7%)
Other medication in hospital
Beta-blocker 26 (89.7%)
ACE-inhibitor and/or ARB 24 (82.8%)
Cholesterol-lowering (statin) 25 (86.2%)
Calcium channel inhibitor 8 (27.6%)
Diuretics 22 (75.9%)
Proton pump inhibitor 12 (41.4%)
Invasive procedures in hospital
Urgent CABG procedure 14 (48.3%)
Coronary angiography 22 (75.9%)
PCI within 24 h of randomization 7 (24.1%)
Any PCI pre-discharge 7 (24.1%)
Any CABG pre-discharge 15 (51.7%)
Values are n (%) or median (interquartile range). Patients underwent CABG within 7 days after the la
elevation1 mm or LBBB or final diagnosis STEMI.
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; LBBB  left bundle
nfarction; other abbreviations as in Table 1.dogrel/placebo. Furthermore, half of the patients random-ized to ticagrelor received open-label clopidogrel pre-
randomization. Therefore, in the real-life setting, the risk
for ischemic and bleeding events when using ticagrelor
instead of clopidogrel could be lower before as well as after
the CABG procedure.
For patients with ACS needing CABG surgery, these
results suggest a preference for ticagrelor over clopidogrel to
reduce ischemic events, long-term complications of bleed-
ing, and most importantly, mortality. Currently, also, pra-
sugrel is approved as an alternative to clopidogrel in ACS
patients treated with PCI procedures (16). Prasugrel, like
clopidogrel, is a thienopyridine and an irreversible platelet
inhibitor. Therefore, pre-treatment levels of platelet activity
are not achieved until 7 to 10 days after cessation of
treatment (17), similar to the recovery time for high
responders to clopidogrel (9). In the TRITON–TIMI 38
(Trial to Assess Improvement in Therapeutic Outcomes by
Optimizing Platelet Inhibition With Prasugrel–Thrombolysis In
Myocardial Infarction 38) study, CABG-related bleeding
events were 4-fold higher in patients treated with prasu-
Index Eventischarge for Index Event
 87) Total (N  1,261)
opidogrel (n  58) Ticagrelor (n  632) Clopidogrel (n  629)
15 (25.9%) 108 (17.1%) 107 (17.0%)
75 (68–90) 72 (64–82) 73 (65–84)
133 (120–149) 131 (120–150) 132 (120–150)
80 (70–90) 80 (70–89) 80 (70–87)
4 (6.9%) 9 (1.4%) 11 (1.8%)
21 (36.2%) 206 (32.6%) 210 (33.4%)
16 (76.2%) 122 (59.2%) 116 (55.2%)
49 (84.5%) 597 (94.5%) 587 (93.3%)
54 (93.1%) 614 (97.2%) 611 (97.1%)
33 (56.9%) 356 (56.3%) 355 (56.4%)
31 (53.4%) 393 (62.2%) 381 (60.6%)
1 (1.7%) 20 (3.2%) 18 (2.9%)
1 (1.7%) 2 (0.3%) 5 (0.8%)
13 (22.4%) 134 (21.2%) 141 (22.4%)
46 (79.3%) 578 (91.5%) 563 (89.5%)
51 (87.9%) 521 (82.4%) 532 (84.6%)
50 (86.2%) 612 (96.8%) 613 (97.5%)
20 (34.5%) 181 (28.6%) 189 (30.0%)
39 (67.2%) 370 (58.5%) 369 (58.7%)
37 (63.8%) 345 (54.6%) 376 (59.8%)
33 (56.9%) 201 (31.9%) 218 (34.7%)
46 (79.3%) 564 (89.2%) 567 (90.1%)
10 (17.2%) 112 (17.7%) 126 (20.0%)
12 (20.7%) 130 (20.6%) 135 (21.5%)
35 (60.3%) 352 (55.7%) 368 (58.5%)
e of the study drug. *TIMI STEMI risk score2 in percentage of patients with persistent ST-segment
h block; STEMI  ST-segment elevation myocardial infarction; TIMI  Thrombolysis In Myocardiale forr at D
ABG (n
Cl
st intakgrel compared with clopidogrel (CABG-related TIMI
1628 Varenhorst et al. JACC Vol. 60, No. 17, 2012
Ticagrelor in Coronary Artery Bypass Surgery October 23, 2012:1623–30Cause of Death for Patients UndergoingABG Within 7 Days From Last Intake of Study DrugTable 3 Cause of D a h for Patie ts UndergoingCABG Within 7 Days From Last Intake of Study Drug
Ticagrelor
(n  632)
Clopidogrel
(n  629) p Value*
Primary cause of vascular death
Sudden death 2 (0.3) 5 (0.8)
Acute myocardial infarction 10 (1.6) 14 (2.2)
Arrhythmia (ventricular fibrillation or other lethal arrhythmias
without known secondary cause)
1 (0.2) 4 (0.6)
Heart failure/cardiogenic shock 6 (0.9) 9 (1.4)
Ischemic stroke 1 (0.2) 1 (0.2)
Hemorrhagic stroke 0 2 (0.3)
Intracranial hemorrhage 0 1 (0.2)
Pulmonary embolism 0 1 (0.2)
Peripheral arterial disease 0 1 (0.2)
Peri/post-operative CABG-related bleeding 1 (0.2) 2 (0.3)
Gastrointestinal bleeding 1 (0.2) 1 (0.2)
Other hemorrhage 0 1 (0.2)
Other vascular death 3 (0.5) 5 (0.8)
Total vascular death 25 (4.0) 47 (7.5) 0.0092
Bleeding related to vascular death
Peri/post-operative CABG-related bleeding 7 (1.1) 12 (1.9)
Gastrointestinal bleeding 0 1 (0.2)
Other 0 2 (0.3)
Total bleeding related to vascular death: no 18 (2.8) 32 (5.1)
Total bleeding related to vascular death: yes 7 (1.1) 15 (2.4) 0.0897
Infection related to vascular death
Surgical site infection 0 3 (0.5)
Blood stream infection 0 1 (0.2)
Respiratory tract infection 2 (0.3) 2 (0.3)
Cardiovascular system infection 0 1 (0.2)
Other 0 1 (0.2)
Total infection related to vascular death: no 23 (3.6) 39 (6.2)
Total infection related to vascular death: yes 2 (0.3) 8 (1.3) 0.0639
Primary cause of nonvascular death
Surgical site infection 0 3 (0.5)
Blood stream infection 0 4 (0.6)
Respiratory tract infection 2 (0.3) 1 (0.2)
Total infection 2 (0.3) 8 (1.3) 0.0639
Gastrointestinal causes (for example, hepatic failure, not bleeding) 1 (0.2) 1 (0.2)
MODS (Multiple Organ Dysfunction Syndrome) 1 (0.2) 1 (0.2)
Suicide 0 1 (0.2)
Total nonvascular death 4 (0.6) 11 (1.7) 0.0748
Bleeding related to nonvascular death
Peri/post-operative CABG related bleeding 0 3 (0.5)
Gastrointestinal bleeding 0 1 (0.2)
Other, please specify 0 1 (0.2)
Total bleeding related to nonvascular death: no 4 (0.6) 6 (1.0)
Total bleeding related to nonvascular death: yes 0 5 (0.8) 0.0306
Infection related to nonvascular death
Respiratory tract infection 1 (0.2) 0
Gastrointestinal system infection 1 (0.2) 0
Total infection related to death: no 2 (0.3) 11 (1.7)
Total infection related to death: yes 2 (0.3) 0 0.4996
Total death (vascular and nonvascular) 29 (4.6) 58 (9.2) 0.0018Values are n (%). *p Values are from Fisher exact test except for total, total vascular, and nonvascular death (Cox proportional hazard analysis).
CABG  coronary artery bypass graft surgery.
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dogrel, respectively), although this did not translate into
higher mortality in the prasugrel group (18).
Infection-related CABG deaths were evenly distributed
over the first 3 months after surgery. It is well known that
infections contribute to an adverse outcome after CABG
surgery (19). Platelets are pivotal contributors to the im-
Figure 2 Kaplan-Meier Estimates of Time to Death
Cumulative Kaplan-Meier estimates of the time to death due to bleeding (pri-
mary cause or contributing) (A) and infection (primary cause or contributing)
(B) after coronary artery bypass grafting surgery (CABG). CI  confidence inter-
val; HR  hazard ratio.
Death After CABG With Infection or Bleeding asirect Cause or Contribution Fact (N  1,261)Table 4 Death Af er CABG With Infection or Bleeding asDirect Cause or Contribution Factor (N  1,261)
Endpoint (Causing or
Contributing to Death)
Ticagrelor
(n  632)*
Clopidogrel
(n  629)* HR (95% CI)† p Value‡
Bleeding 9 (1.4) 27 (4.6) 0.33 (0.15–0.70) 0.0038
Infection 6 (1.0) 16 (2.9) 0.36 (0.14–0.93) 0.0349
Values are n (%). *The Kaplan-Meier estimate of the rate of the endpoint at 12 months post-CABG is
shown; †hazard ratios (HR) are for ticagrelor versus clopidogrel and are derived from Cox proportional
hazardsmodel with the treatment group (ticagrelor/clopidogrel) as independent variable; ‡p values are
for the null hypothesis of no difference between treatment groups and are derived from Cox propor-
tional hazards model with the treatment group (ticagrelor/clopidogrel) as independent variable.
CABG  coronary artery bypass graft surgery; CI  confidence interval.mune response in infection, and an up-regulated platelet
activation in septic patients leads to organ hypoperfusion,
pathological tissue injury, and poor patient outcomes (20).
Despite growing evidence to suggest a pathophysiological
role for platelets in inflammatory conditions, there is no, or
very little, evidence to support a targeted antiplatelet treat-
ment in afflicted patients. In contrast to pre-clinical results,
suggesting a potential benefit of antiplatelet treatment in
infection (21), a retrospective study has suggested an in-
creased risk of infection in clopidogrel-treated patients
undergoing CABG compared with those treated with aspi-
rin alone (22). The mechanisms by which clopidogrel may
increase the risk of infection-related mortality are not
known, although clopidogrel treatment has been associated
with aplastic anemia, thrombocytopenia, and neutropenia
(23). The higher rate of infections with clopidogrel may also
Figure 3 Time to Death Due to Bleeding or Infection
Time to death due to bleeding (primary cause or contributing) (A) and infection
(primary cause or contributing) (B) after coronary artery bypass grafting surgery
(CABG).be directly related to more bleeding, as patients who bleed
1630 Varenhorst et al. JACC Vol. 60, No. 17, 2012
Ticagrelor in Coronary Artery Bypass Surgery October 23, 2012:1623–30are more likely to have prolonged drainage tube placements
and length of hospitalization. The impact of antiplatelet
agents, such as clopidogrel and ticagrelor, on circulating
platelets, markers of inflammation, and clinical outcomes
during systemic infection, needs to be further clarified.
Study limitations. The analysis was a retrospective inves-
tigation of a post-randomization–identified cohort with
post hoc–blinded classification of specific causes of death by
subcategorizing the vascular and nonvascular deaths identi-
fied in the main study. The results should therefore be
regarded as exploratory and hypothesis generating. How-
ever, we sought to limit bias by a process in which reviewers
identified and agreed on the different categories prior to
examining case records and performed all reviews blinded to
study treatment.
Conclusions
In ACS patients receiving dual antiplatelet therapy within 7
days of CABG, ticagrelor, compared with clopidogrel, was
associated with fewer deaths related to cardiovascular,
bleeding, and infection events. The cause-of-death pattern
was similar between treatment groups. Further studies are
needed to investigate the underlying mechanisms responsi-
ble for the better survival after CABG in patients with ACS
treated with ticagrelor.
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